Clinical Trials in Wuxi, China
32 recruiting
Showing 1–20 of 60 trials
Recruiting
Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 3
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Severe Asthma
AstraZeneca400 enrolled75 locationsNCT07363642
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled155 locationsNCT06943872
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled212 locationsNCT06345729
Recruiting
Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Gastric CancerGastroesophageal-junction Cancer
Daiichi Sankyo726 enrolled250 locationsNCT06731478
Recruiting
Not Applicable
The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases
Cardiovascular Diseases
AstraZeneca3,000 enrolled69 locationsNCT06909773
Recruiting
Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca1,145 enrolled305 locationsNCT06129864
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled217 locationsNCT06170788
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Crohn's Disease
Merck Sharp & Dohme LLC1,200 enrolled497 locationsNCT06430801
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled281 locationsNCT06136624
Recruiting
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Hypertension
Eli Lilly and Company974 enrolled101 locationsNCT06948422
Recruiting
Phase 3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
DementiaBrain DiseasesCentral Nervous System Diseases+6 more
Eli Lilly and Company1,500 enrolled141 locationsNCT05508789
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled320 locationsNCT06136650
Recruiting
Phase 2
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
Ulcerative Colitis
Sanofi99 enrolled65 locationsNCT06975722
Recruiting
Phase 2
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
Pulmonary Disease, Chronic Obstructive
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.195 enrolled29 locationsNCT07252908
Recruiting
Not Applicable
Hyperkalemia Quality Improvement Program (HK-QIP) Study
Hyperkalemia
AstraZeneca1,000 enrolled49 locationsNCT06884267
Recruiting
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Hypertension
Eli Lilly and Company487 enrolled99 locationsNCT06952530
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Carcinoma, Non-Small Cell Lung
Hoffmann-La Roche800 enrolled36 locationsNCT06862869